{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T05:37:44Z","timestamp":1793079464031,"version":"4.5.0"},"reference-count":10,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"1","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Methamphetamine is an addictive stimulant that may induce symptoms of agitation and psychosis. The estimated rate of methamphetamine use is 6.6 per 1000 people. Currently, no treatment guidelines exist to support the optimal management of patients presenting with methamphetamine-induced agitation. Emergency department (ED) providers may prescribe various benzodiazepines (BZDs) and antipsychotics (APs) as first-line agents to stabilize these agitated patients. This study aims to determine the effectiveness of a protocol to guide management of this condition.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a retrospective, pre- and poststudy conducted from July 2020 to March 2021 at a large academic medical center. A multidisciplinary protocol was designed to help manage methamphetamine-induced agitation in the ED. The primary outcome of the study was a reduction in the number of BZDs and APs used for the treatment of methamphetamine-induced agitation. This was measured by the incidence of overprescribing, defined as 3 or more APs or BZDs administered within 30 minutes. Secondary outcomes included the use of physical restraints, ED length of stay, and adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We did not observe a significantly lower incidence of overprescribing, adverse events, or ED length of stay when comparing pre- and postprotocol groups. A subgroup analysis demonstrated that when protocol was followed, there was a statistically significant reduction in overprescribing (P\u2009=\u2009.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>We did not find any differences among our primary and secondary outcomes, which may be attributed to protocol nonadherence. Full compliance to the protocol may reduce the rate of overprescribing APs or BZDs in patients with methamphetamine-induced agitation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.9740\/mhc.2022.01.009","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T16:57:51Z","timestamp":1642784271000},"page":"9-14","source":"Crossref","is-referenced-by-count":6,"title":["Evaluating the impact of an emergency department protocol that guides management of methamphetamine-induced agitation and psychosis"],"prefix":"10.9740","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7836-9017","authenticated-orcid":true,"given":"Julie","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0341-8093","authenticated-orcid":true,"given":"Stephen","family":"Lee","sequence":"additional","affiliation":[{"name":"Pharmacist, UC Irvine Health Medical Center, Orange, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0539-821X","authenticated-orcid":true,"given":"Dennis","family":"Ankrah","sequence":"additional","affiliation":[{"name":"Pharmacist, UC Irvine Health Medical Center, Orange, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0470-5238","authenticated-orcid":true,"given":"Erin","family":"Knox","sequence":"additional","affiliation":[{"name":"Pharmacist Education Specialist, Department of Pharmacy, UC Irvine Health Medical Center, Orange, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4719","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"2022012116474607600_i2168-9709-12-1-9-b01","doi-asserted-by":"crossref","unstructured":"Bramness\n              JG,\n            \n            \n              Gundersen\n              \u00d8H,\n            \n            \n              Guterstam\n              J,\n            \n            \n              Rognli\n              EB,\n            \n            \n              Konstenius\n              M,\n            \n            \n              L\u00f8berg\n              EM,\n            \n            et al.\n          \n          Amphetamine-induced psychosis--a separate diagnostic entity or primary psychosis triggered in the vulnerable?\n          BMC Psychiatry.\n\t\t\t\t\t2012;\n\t\t\t\t\t12(1):\n\t\t\t\t\t221.\n\t\t\t\t\tDOI: 10.1186\/1471-244X-12-221. PubMed PMID: 23216941; PubMed Central PMCID: PMC3554477.","DOI":"10.1186\/1471-244X-12-221"},{"key":"2022012116474607600_i2168-9709-12-1-9-b02","doi-asserted-by":"crossref","unstructured":"Jones\n              CM,\n            \n            \n              Compton\n              WM,\n            \n            \n              Mustaquim\n              D.\n            \n          \n          Patterns and characteristics of methamphetamine use among adults--United States, 2015\u20132018.\n\t\t\t\t\tMMWR Morb Mortal Wkly Rep.\n\t\t\t\t\t2020;\n\t\t\t\t\t69(12):\n\t\t\t\t\t317-\n\t\t\t\t\t23.\n\t\t\t\t\tDOI: 10.15585\/mmwr.mm6912a1. PubMed PMID: 32214077; PubMed Central PMCID: PMC7725509.","DOI":"10.15585\/mmwr.mm6912a1"},{"key":"2022012116474607600_i2168-9709-12-1-9-b03","doi-asserted-by":"crossref","unstructured":"Pasic\n              J,\n            \n            \n              Russo\n              JE,\n            \n            \n              Ries\n              RK,\n            \n            \n              Roy-Byrne\n              PP.\n            \n          \n          Methamphetamine users in the psychiatric emergency services: a case-control study.\n\t\t\t\t\tAm J Drug Alcohol Abuse.\n\t\t\t\t\t2007;\n\t\t\t\t\t33(5):\n\t\t\t\t\t675-\n\t\t\t\t\t86.\n\t\t\t\t\tDOI: 10.1080\/00952990701522732. PubMed PMID: 17891660.","DOI":"10.1080\/00952990701522732"},{"key":"2022012116474607600_i2168-9709-12-1-9-b04","doi-asserted-by":"crossref","unstructured":"Winkelman\n              TNA,\n            \n            \n              Admon\n              LK,\n            \n            \n              Jennings\n              L,\n            \n            \n              Shippee\n              ND,\n            \n            \n              Richardson\n              CR,\n            \n            \n              Bart\n              G.\n            \n          \n          Evaluation of amphetamine-related hospitalizations and associated clinical outcomes and costs in the United States.\n\t\t\t\t\tJAMA Netw Open.\n\t\t\t\t\t2018;\n\t\t\t\t\t1(6):\n\t\t\t\t\te183758.\n\t\t\t\t\tDOI: 10.1001\/jamanetworkopen.2018.3758. PubMed PMID: 30646256.","DOI":"10.1001\/jamanetworkopen.2018.3758"},{"key":"2022012116474607600_i2168-9709-12-1-9-b05","doi-asserted-by":"crossref","unstructured":"Wodarz\n              N,\n            \n            \n              Krampe-Scheidler\n              A,\n            \n            \n              Christ\n              M,\n            \n            \n              Fleischmann\n              H,\n            \n            \n              Looser\n              W,\n            \n            \n              Schoett\n              K,\n            \n            et al.\n          \n          Evidence-based guidelines for the pharmacological management of acute methamphetamine-related disorders and toxicity.\n\t\t\t\t\tPharmacopsychiatry.\n\t\t\t\t\t2017;\n\t\t\t\t\t50(3):\n\t\t\t\t\t87-\n\t\t\t\t\t95.\n\t\t\t\t\tDOI: 10.1055\/s-0042-123752. PubMed PMID: 28297728.","DOI":"10.1055\/s-0042-123752"},{"key":"2022012116474607600_i2168-9709-12-1-9-b06","doi-asserted-by":"crossref","unstructured":"Wilson\n              MP,\n            \n            \n              Pepper\n              D,\n            \n            \n              Currier\n              GW,\n            \n            \n              Holloman\n              GH,\n            \n            \n              Feifel\n              D.\n            \n          \n          The psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry Project Beta psychopharmacology workgroup.\n\t\t\t\t\tWest J Emerg Med.\n\t\t\t\t\t2012;\n\t\t\t\t\t13(1):\n\t\t\t\t\t26-\n\t\t\t\t\t34.\n\t\t\t\t\tDOI: 10.5811\/westjem.2011.9.6866. PubMed PMID: 22461918; PubMed Central PMCID: PMC3298219.","DOI":"10.5811\/westjem.2011.9.6866"},{"key":"2022012116474607600_i2168-9709-12-1-9-b07","doi-asserted-by":"crossref","unstructured":"Fluyau\n              D,\n            \n            \n              Mitra\n              P,\n            \n            \n              Lorthe\n              K.\n            \n          \n          Antipsychotics for amphetamine psychosis; a systematic review.\n\t\t\t\t\tFront Psychiatry.\n\t\t\t\t\t2019;\n\t\t\t\t\t10:\n\t\t\t\t\t740.\n\t\t\t\t\tDOI: 10.3389\/fpsyt.2019.00740. PubMed PMID: 31681046.","DOI":"10.3389\/fpsyt.2019.00740"},{"key":"2022012116474607600_i2168-9709-12-1-9-b08","unstructured":"Eli Lilly and Company.\n          ZYPREXA (olanzapine) tablet, 2009 [cited 2021 Jul 3].\n\t\t\t\t\tIn:DailyMed [Internet].\n\t\t\t\t\tBethesda (MD):\n\t\t\t\t\tNational Library of Medicine.\n\t\t\t\t\tAvailable from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=66ef201f-85eb-44f0-9ef0-1b618c6e0bff"},{"key":"2022012116474607600_i2168-9709-12-1-9-b09","doi-asserted-by":"crossref","unstructured":"Williams\n              AM.\n            \n          \n          Coadministration of intramuscular olanzapine and benzodiazepines in agitated patients with mental illness.\n\t\t\t\t\tMent Health Clin [Internet].\n\t\t\t\t\t2018;\n\t\t\t\t\t8(5):\n\t\t\t\t\t208-\n\t\t\t\t\t13.\n\t\t\t\t\tDOI: 10.9740\/mhc.2018.09.208. PubMed PMID: 30206503; PubMed Central PMCID: PMC6125121.","DOI":"10.9740\/mhc.2018.09.208"},{"key":"2022012116474607600_i2168-9709-12-1-9-b10","doi-asserted-by":"crossref","unstructured":"Chan\n              EW,\n            \n            \n              Taylor\n              DM,\n            \n            \n              Knott\n              JC,\n            \n            \n              Phillips\n              GA,\n            \n            \n              Castle\n              DJ,\n            \n            \n              Kong\n              DCM.\n            \n          \n          Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double-blind, placebo-controlled clinical trial.\n\t\t\t\t\tAnn Emerg Med.\n\t\t\t\t\t2013;\n\t\t\t\t\t61(1):\n\t\t\t\t\t72-\n\t\t\t\t\t81.\n\t\t\t\t\tDOI: 10.1016\/j.annemergmed.2012.07.118. PubMed PMID: 22981685.","DOI":"10.1016\/j.annemergmed.2012.07.118"}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/mhc\/article-pdf\/12\/1\/9\/3006513\/i2168-9709-12-1-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/mhc\/article-pdf\/12\/1\/9\/3006513\/i2168-9709-12-1-9.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:23:47Z","timestamp":1731687827000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/12\/1\/article-p9.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,21]]},"published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2022.01.009","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,1]]}}}